Cox regression analyses of baseline laboratory and imaging parameters associated with overall and event-free survival without and with gene array-derived parameters
| Model . | n/N (%) . | Overall survival from start of therapy . | Event-free survival from start of therapy . | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P* . | R2, percentage . | HR (95% CI) . | P* . | R2, percentage . | ||
| Univariate | |||||||
| Standard variables | |||||||
| Age ≥ 65 y | 68/239 (28) | 1.40 (0.78-2.52) | .258 | 2.4 | 1.56 (0.94-2.60) | .088 | 4.0 |
| Albumin < 3.5 g/dL | 62/239 (26) | 1.70 (0.95-3.06) | .076 | 5.7 | 1.73 (1.03-2.90) | .038 | 5.5 |
| B2M ≥ 3.5 mg/L | 108/239 (45) | 1.89 (1.08-3.31) | .027 | 9.4 | 1.85 (1.13-3.04) | .015 | 8.9 |
| B2M > 5.5 mg/L | 52/239 (22) | 3.14 (1.79-5.51) | < .001 | 19.1 | 3.29 (2.00-5.41) | < .001 | 19.6 |
| Creatinine ≥ 2 mg/dL | 17/239 (7) | 1.56 (0.62-3.94) | .343 | 1.4 | 2.10 (1.00-4.41) | .049 | 3.7 |
| CRP ≥ 8 mg/L | 79/238 (33) | 1.59 (0.91-2.79) | .107 | 4.6 | 1.51 (0.92-2.49) | .105 | 3.8 |
| Hb < 10 g/dL | 77/239 (32) | 1.89 (1.08-3.30) | .025 | 8.2 | 1.79 (1.09-2.93) | .021 | 6.8 |
| LDH ≥ 190 U/L | 56/239 (23) | 3.02 (1.72-5.31) | < .001 | 19.5 | 3.22 (1.96-5.31) | < .001 | 29.9 |
| Genetic variables | |||||||
| Cytogenetic abnormalities | 82/239 (34) | 2.83 (1.62-4.95) | < .001 | 20.4 | 2.10 (1.28-3.43) | .003 | 11.3 |
| GEP high-risk | 32/216 (15) | 3.61 (1.93-6.75) | < .001 | 16.6 | 3.44 (1.96-6.04) | < .001 | 15.8 |
| Imaging variables | |||||||
| MRI-FL > 7 | 68/239 (28) | 1.61 (0.91-2.85) | .104 | 4.4 | 1.71 (1.04-2.83) | .036 | 5.6 |
| MBS-OL > 2 | 75/239 (31) | 2.28 (1.31-3.97) | .004 | 13.1 | 2.22 (1.36-3.64) | .001 | 12.2 |
| PET-FL > 3 | 82/239 (34) | 2.79 (1.60-4.88) | < .001 | 20.2 | 2.88 (1.76-4.73) | < .001 | 20.8 |
| CT-OL > 50 | 18/239 (8) | 1.26 (0.45-3.52) | .657 | 0.6 | 1.20 (0.48-3.01) | .691 | 0.4 |
| SUV-FL > 3.9 | 101/239 (42) | 1.74 (1.00-3.04) | .052 | 7.0 | 1.78 (1.09-2.92) | .022 | 7.7 |
| EMD | 14/239 (6) | 3.26 (1.46-7.24) | .004 | 7.2 | 3.54 (1.75-7.18) | < .001 | 8.1 |
| Multivariate without gene array data† | |||||||
| Cytogenetic abnormalities | 82/238 (34) | 2.88 (1.59-5.19) | < .001 | 20.4 | 1.85 (1.09-3.13) | .022 | 11.3 |
| PET-FL > 3 | 81/238 (34) | 2.43 (1.37-4.30) | .002 | 33.3 | 2.28 (1.37-3.80) | .002 | 28.8 |
| LDH ≥ 190 U/L | 56/238 (24) | 2.04 (1.13-3.68) | .017 | 42.3 | 2.00 (1.17-3.42) | .012 | 36.1 |
| B2M > 5.5 mg/L | 52/238 (22) | NS | NS | NS | 1.83 (1.05-3.20) | .033 | 42.0 |
| EMD | 14/238 (6) | 3.13 (1.34-7.31) | .008 | 44.5 | 2.29 (1.05-4.99) | .038 | 45.7 |
| Multivariate with gene array data† | |||||||
| Cytogenetic abnormalities | 77/215 (36) | 2.62 (1.37-5.02) | .004 | 20.4 | 1.83 (1.04-3.21) | .036 | 51.6 |
| PET-FL > 3 | 73/215 (34) | 2.45 (1.30-4.62) | .006 | 33.3 | 2.63 (1.51-4.58) | < .001 | 32.6 |
| LDH ≥ 190 U/L | 50/215 (23) | 2.28 (1.22-4.28) | .010 | 37.4 | 2.38 (1.37-4.13) | .002 | 20.9 |
| Albumin < 3.5 g/dL | 57/215 (27) | 2.11 (1.11-4.03) | .023 | 38.1 | 2.20 (1.26-3.86) | .006 | 51.2 |
| GEP high-risk | 32/215 (15) | 1.76 (0.89-3.50) | .104 | 44.0 | 1.86 (1.00-3.44) | .048 | 46.7 |
| Model . | n/N (%) . | Overall survival from start of therapy . | Event-free survival from start of therapy . | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P* . | R2, percentage . | HR (95% CI) . | P* . | R2, percentage . | ||
| Univariate | |||||||
| Standard variables | |||||||
| Age ≥ 65 y | 68/239 (28) | 1.40 (0.78-2.52) | .258 | 2.4 | 1.56 (0.94-2.60) | .088 | 4.0 |
| Albumin < 3.5 g/dL | 62/239 (26) | 1.70 (0.95-3.06) | .076 | 5.7 | 1.73 (1.03-2.90) | .038 | 5.5 |
| B2M ≥ 3.5 mg/L | 108/239 (45) | 1.89 (1.08-3.31) | .027 | 9.4 | 1.85 (1.13-3.04) | .015 | 8.9 |
| B2M > 5.5 mg/L | 52/239 (22) | 3.14 (1.79-5.51) | < .001 | 19.1 | 3.29 (2.00-5.41) | < .001 | 19.6 |
| Creatinine ≥ 2 mg/dL | 17/239 (7) | 1.56 (0.62-3.94) | .343 | 1.4 | 2.10 (1.00-4.41) | .049 | 3.7 |
| CRP ≥ 8 mg/L | 79/238 (33) | 1.59 (0.91-2.79) | .107 | 4.6 | 1.51 (0.92-2.49) | .105 | 3.8 |
| Hb < 10 g/dL | 77/239 (32) | 1.89 (1.08-3.30) | .025 | 8.2 | 1.79 (1.09-2.93) | .021 | 6.8 |
| LDH ≥ 190 U/L | 56/239 (23) | 3.02 (1.72-5.31) | < .001 | 19.5 | 3.22 (1.96-5.31) | < .001 | 29.9 |
| Genetic variables | |||||||
| Cytogenetic abnormalities | 82/239 (34) | 2.83 (1.62-4.95) | < .001 | 20.4 | 2.10 (1.28-3.43) | .003 | 11.3 |
| GEP high-risk | 32/216 (15) | 3.61 (1.93-6.75) | < .001 | 16.6 | 3.44 (1.96-6.04) | < .001 | 15.8 |
| Imaging variables | |||||||
| MRI-FL > 7 | 68/239 (28) | 1.61 (0.91-2.85) | .104 | 4.4 | 1.71 (1.04-2.83) | .036 | 5.6 |
| MBS-OL > 2 | 75/239 (31) | 2.28 (1.31-3.97) | .004 | 13.1 | 2.22 (1.36-3.64) | .001 | 12.2 |
| PET-FL > 3 | 82/239 (34) | 2.79 (1.60-4.88) | < .001 | 20.2 | 2.88 (1.76-4.73) | < .001 | 20.8 |
| CT-OL > 50 | 18/239 (8) | 1.26 (0.45-3.52) | .657 | 0.6 | 1.20 (0.48-3.01) | .691 | 0.4 |
| SUV-FL > 3.9 | 101/239 (42) | 1.74 (1.00-3.04) | .052 | 7.0 | 1.78 (1.09-2.92) | .022 | 7.7 |
| EMD | 14/239 (6) | 3.26 (1.46-7.24) | .004 | 7.2 | 3.54 (1.75-7.18) | < .001 | 8.1 |
| Multivariate without gene array data† | |||||||
| Cytogenetic abnormalities | 82/238 (34) | 2.88 (1.59-5.19) | < .001 | 20.4 | 1.85 (1.09-3.13) | .022 | 11.3 |
| PET-FL > 3 | 81/238 (34) | 2.43 (1.37-4.30) | .002 | 33.3 | 2.28 (1.37-3.80) | .002 | 28.8 |
| LDH ≥ 190 U/L | 56/238 (24) | 2.04 (1.13-3.68) | .017 | 42.3 | 2.00 (1.17-3.42) | .012 | 36.1 |
| B2M > 5.5 mg/L | 52/238 (22) | NS | NS | NS | 1.83 (1.05-3.20) | .033 | 42.0 |
| EMD | 14/238 (6) | 3.13 (1.34-7.31) | .008 | 44.5 | 2.29 (1.05-4.99) | .038 | 45.7 |
| Multivariate with gene array data† | |||||||
| Cytogenetic abnormalities | 77/215 (36) | 2.62 (1.37-5.02) | .004 | 20.4 | 1.83 (1.04-3.21) | .036 | 51.6 |
| PET-FL > 3 | 73/215 (34) | 2.45 (1.30-4.62) | .006 | 33.3 | 2.63 (1.51-4.58) | < .001 | 32.6 |
| LDH ≥ 190 U/L | 50/215 (23) | 2.28 (1.22-4.28) | .010 | 37.4 | 2.38 (1.37-4.13) | .002 | 20.9 |
| Albumin < 3.5 g/dL | 57/215 (27) | 2.11 (1.11-4.03) | .023 | 38.1 | 2.20 (1.26-3.86) | .006 | 51.2 |
| GEP high-risk | 32/215 (15) | 1.76 (0.89-3.50) | .104 | 44.0 | 1.86 (1.00-3.44) | .048 | 46.7 |
HR indicates hazard ratio; CI, confidence interval; and NS, not statistically significant at the .05 level.
P value from Wald χ2 test in Cox regression. Multivariate model uses stepwise selection with entry level .1 and variable remains if it meets the .05 level. Variables considered for stepwise selection include albumin, β-2-microglobulin (B2M), hemoglobin (Hb), lactate dehydrogenase (LDH), C-reactive protein (CRP), cytogenetic abnormalities (CA), and gene expression profiling (GEP) high-risk; imaging parameters include MRI-FL, MBS-OL, PET-FL, SUV-FL, and EMD.
Data reported in the R2 columns for the multivariate models are cumulative. The variable with smallest R2 is first to enter model; the next smallest is second to enter; the largest R2 is last to enter.